Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound DebridementNewly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
MediWound to Present New EscharEx® Data at Leading Wound Care ConferencesMediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Files Annual Report on Form 20-FMediWound Files Annual Report on Form 20-F
MediWound to Report Fourth Quarter and Full Year 2025 Financial ResultsMediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound to Present at Upcoming Investor ConferencesMediWound to Present at Upcoming Investor Conferences
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast InjuriesMediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateOngoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers
MediWound to Report Third Quarter 2025 Financial ResultsMediWound to Report Third Quarter 2025 Financial Results
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
MediWound Announces $30 Million Registered Direct Offering of Ordinary SharesMediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressMediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference.
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg UlcersMediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound to Report Second Quarter 2025 Financial ResultsMediWound to Report Second Quarter 2025 Financial Results
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg UlcersPost hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®
MediWound to Report First Quarter 2025 Financial ResultsConference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
MediWound to Present New EscharEx® Data at Leading Wound Care ConferencesPresentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs
MediWound to Report Fourth Quarter and Full Year 2024 Financial ResultsConference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time
